Compare CVS Health Corp (CVS) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Banco Santander SA — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Banco Santander SA trades at $14.78 (market cap $211.88B). The key difference: Banco Santander SA is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | SAN | |
|---|---|---|
Market Cap | $122.36B | $211.88B |
Sector | Health | Financials |
52-Week High | $110.60 | $14.71 |
52-Week Low | $65.51 | $9.37 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Banco Santander (SAN) trades at $14.70, up 0.34% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.39, net income margin of 26.25% for 2026, and record profits in H1 2026. Recent news highlights Federal Reserve approval for its $12 billion Webster Bank acquisition, expected to close August 20, 2026, and its rise as Spain's most valuable company.
Outlook is positive given analyst consensus (64% buy ratings), solid profitability, and strategic acquisitions, but risks include regulatory scrutiny in Spain, volatile cash flows, and earnings misses in two of the last three quarters. The stock offers value with growth potential amid integration execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
